Mizuho raised the firm’s price target on Ideaya Biosciences (IDYA) to $44 from $43 and keeps an Outperform rating on the shares following the research and development day. The firm left impressed by Ideaya’s ability to execute. Mizuho increased its probability of success for Ideaya’s lead asset darovasertib in uveal melanoma to 70% from 60%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Promising Clinical Developments and Strategic Positioning Highlighted by Buy Rating
- Ideaya Biosciences price target raised to $38 from $36 at RBC Capital
- Promising Pipeline and Competitive Edge: IDEAYA Biosciences Receives Buy Rating from Analyst
- Ideaya should be bought on yesterday’s selloff, says Wells Fargo
- Ideaya Biosciences selloff on R&D day overdone, says Citi